Exact Mass: 467.33755700000006
Exact Mass Matches: 467.33755700000006
Found 233 metabolites which its exact mass value is equals to given mass value 467.33755700000006,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Delsoline
C25H41NO7 (467.28828760000005)
Delsoline is a diterpenoid. Delsoline is a natural product found in Aconitum barbatum, Aconitum monticola, and other organisms with data available. Origin: Plant; SubCategory_DNP: Terpenoid alkaloids, Diterpene alkaloid, Aconitum alkaloid Delsoline, a major alkaloid of Delphinium anthriscifolium Hance, has both a curare-like effect and a ganglion-blocking effect and is used to relieve muscle tension or hyperkinesia. D. anthriscifolium Hance has effects of dispelling wind and dampness, activating collaterals, and relieving pains and is used to treat rheumatism, hemiplegia, indigestion, and cough[1]. Delsoline, a major alkaloid of Delphinium anthriscifolium Hance, has both a curare-like effect and a ganglion-blocking effect and is used to relieve muscle tension or hyperkinesia. D. anthriscifolium Hance has effects of dispelling wind and dampness, activating collaterals, and relieving pains and is used to treat rheumatism, hemiplegia, indigestion, and cough[1].
Buprenorphine
C29H41NO4 (467.30354260000007)
A derivative of the opioid alkaloid thebaine that is a more potent and longer lasting analgesic than morphine. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use. [PubChem] N - Nervous system > N07 - Other nervous system drugs > N07B - Drugs used in addictive disorders > N07BC - Drugs used in opioid dependence D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AE - Oripavine derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists D002491 - Central Nervous System Agents > D000700 - Analgesics
Oxethazaine
C28H41N3O3 (467.3147756000001)
C - Cardiovascular system > C05 - Vasoprotectives > C05A - Agents for treatment of hemorrhoids and anal fissures for topical use > C05AD - Local anesthetics D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent Same as: D01152
Browniine
C25H41NO7 (467.28828760000005)
Lucidine B
C30H49N3O (467.38754240000003)
LysoPC(14:0/0:0)
LysoPC(14:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(14:0), in particular, consists of one chain of myristic acid at the C-1 position. The myristic acid moiety is derived from nutmeg and butter. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. [HMDB] LysoPC(14:0/0:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(14:0/0:0), in particular, consists of one chain of myristic acid at the C-1 position. The myristic acid moiety is derived from nutmeg and butter. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. LysoPC(14:0/0:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. LysoPC(14:0/0:0) has potent antispasmodic effect[1].
LysoPE (17:0/0:0)
1-Heptadecanoylglycerophosphoethanolamine is a phosphatidylethanolamine. It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE(17:0/0:0), in particular, consists of two heptadecanoyl chains at positions C-1 and C-2. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS.
Tiropramide
C28H41N3O3 (467.3147756000001)
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AC - Synthetic antispasmodics, amides with tertiary amines D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent Tiropramide (INN) is an antispasmodic.
N-Arachidonoyl tyrosine
C29H41NO4 (467.30354260000007)
N-arachidonoyl tyrosine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Arachidonic acid amide of Tyrosine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Arachidonoyl tyrosine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Arachidonoyl tyrosine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
(8Z,11Z)-3-Icosa-8,11-dienoylcarnitine
C27H49NO5 (467.36105440000006)
(8Z,11Z)-3-Icosa-8,11-dienoylcarnitine is an acylcarnitine. More specifically, it is an (8Z,11Z)-3-hydroxyicosa-8,11-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (8Z,11Z)-3-Icosa-8,11-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (8Z,11Z)-3-Icosa-8,11-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(11Z,14Z)-3-Icosa-11,14-dienoylcarnitine
C27H49NO5 (467.36105440000006)
(11Z,14Z)-3-Icosa-11,14-dienoylcarnitine is an acylcarnitine. More specifically, it is an (11Z,14Z)-3-hydroxyicosa-11,14-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (11Z,14Z)-3-Icosa-11,14-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (11Z,14Z)-3-Icosa-11,14-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(1S,2S,6R,15S,16R)-5-(Cyclopropylmethyl)-16-(2-hydroxy-3,3-dimethylbutan-2-yl)-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol
C29H41NO4 (467.30354260000007)
20-ethyl-6beta,14alpha,16beta-trimethoxy-4-methoxymethyl-aconitane-3alpha,7,8-triol|Acomonin|acomonine
C25H41NO7 (467.28828760000005)
(23R)-3beta-Acetoxy-17,23-epoxy-veratra-5,12-dien-11-on|(23R)-3beta-acetoxy-17,23-epoxy-veratra-5,12-dien-11-one|3-O-acetyljervine|O-acetyl-jervine|O-acetyljervine
C29H41NO4 (467.30354260000007)
Semicarbazone-Stigmasta-4,22-dien-3-one,
C30H49N3O (467.38754240000003)
buprenorphine
C29H41NO4 (467.30354260000007)
A morphinane alkaloid that is 7,8-dihydromorphine 6-O-methyl ether in which positions 6 and 14 are joined by a -CH2CH2- bridge, one of the hydrogens of the N-methyl group is substituted by cyclopropyl, and a hydrogen at position 7 is substituted by a 2-hydroxy-3,3-dimethylbutan-2-yl group. It is highly effective for the treatment of opioid use disorder and is also increasingly being used in the treatment of chronic pain. N - Nervous system > N07 - Other nervous system drugs > N07B - Drugs used in addictive disorders > N07BC - Drugs used in opioid dependence D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AE - Oripavine derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists D002491 - Central Nervous System Agents > D000700 - Analgesics
(1S,4S,9S,13S,16S,18S,5R,8R)-11-ethyl-13-(hydroxymethyl)-4,6,16,18-tetramethoxy-11-azahexacyclo(7.7.2.1(2,5).0(1,10).0(3,8).0(13,17))nonadecane-8,9-diol
C25H41NO7 (467.28828760000005)
Origin: Plant; Formula(Parent): C25H41NO7; Bottle Name:Lycoctonine; PRIME Parent Name:Lycoctonine; PRIME in-house No.:V0307; SubCategory_DNP: Terpenoid alkaloids, Diterpene alkaloid, Aconitum alkaloid
Platelet-activating factor
PC(O-14:0/O-1:0)
C23H50NO6P (467.33755700000006)
PC(O-14:0/O-1:0)[S]
C23H50NO6P (467.33755700000006)
PC(O-14:0/O-1:0)[U]
C23H50NO6P (467.33755700000006)
PC(14:0/0:0)
PC(14:0/0:0)[U]
PC(0:0/14:0)
PC(O-15:0/0:0)
C23H50NO6P (467.33755700000006)
Tiropramide
C28H41N3O3 (467.3147756000001)
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AC - Synthetic antispasmodics, amides with tertiary amines D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent
LPC 14:0
LysoPC(14:0/0:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. LysoPC(14:0/0:0) has potent antispasmodic effect[1].
Glycodeoxycholic acid
Deoxycholic acid glycine conjugate, or Deoxygcholylglycine, is an acyl glycine and a bile acid-glycine conjugate. It is a secondary bile acid produced by the action of enzymes existing in the microbial flora of the colonic environment. In hepatocytes, both primary and secondary bile acids undergo amino acid conjugation at the C-24 carboxylic acid on the side chain, and almost all bile acids in the bile duct therefore exist in a glycine conjugated form (PMID:16949895). As a bile salt it acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and choleretic. [HMDB]
ammonium 1,4-dinonyl sulphonatosuccinate
C22H45NO7S (467.29165800000004)
Trimethylolpropane tris(2-methyl-1-aziridinepropionate)
C24H41N3O6 (467.29952060000005)
N-cycloheptyl-6,7-dimethoxy-2-(4-piperidin-1-ylpiperidin-1-yl)quinazolin-4-amine
Oxethazaine
C28H41N3O3 (467.3147756000001)
C - Cardiovascular system > C05 - Vasoprotectives > C05A - Agents for treatment of hemorrhoids and anal fissures for topical use > C05AD - Local anesthetics D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent
[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] heptadecanoate
(2S,4aS,6aS,6bR,12aS)-2,4a,6a,6b,9,9,12a-heptamethyl-10,13-dioxo-1,3,4,5,6,6a,7,8,8a,11,12,14b-dodecahydropicene-2-carboxylate
C30H43O4- (467.31611780000003)
(8Z,11Z)-3-Icosa-8,11-dienoylcarnitine
C27H49NO5 (467.36105440000006)
(11Z,14Z)-3-Icosa-11,14-dienoylcarnitine
C27H49NO5 (467.36105440000006)
(2S)-3-(4-hydroxyphenyl)-2-[[(5Z,8E,11Z,14Z)-icosa-5,8,11,14-tetraenoyl]amino]propanoic acid
C29H41NO4 (467.30354260000007)
2-azaniumylethyl (2R)-3-(heptadecanoyloxy)-2-hydroxypropyl phosphate
O-[(3R,11Z,14Z)-3-hydroxyicosadienoyl]carnitine
C27H49NO5 (467.36105440000006)
An O-acylcarnitine in which the O-acyl group is specified as (3R,11Z,14Z)-3-hydroxyicosadienoyl.
[(2R)-2-methoxy-3-tetradecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C23H50NO6P (467.33755700000006)
2-methyl-3-tetradecyl-sn-glycero-1-phosphocholine
C23H50NO6P (467.33755700000006)
(1S,4S,5R,6R,8R,9S,10S,13S,16S)-11-ethyl-13-(hydroxymethyl)-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecane-8,9-diol
C25H41NO7 (467.28828760000005)
(2-Acetyloxy-3-dodecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
(1S,2R,3R,4S,5R,6S,8R,9S,10R,13S,16S,17R,18S)-11-ethyl-13-(hydroxymethyl)-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecane-8,9-diol
C25H41NO7 (467.28828760000005)
2-Aminoethyl (2-hydroxy-3-octadecoxypropyl) hydrogen phosphate
C23H50NO6P (467.33755700000006)
(2-Hydroxy-3-pentadecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C23H50NO6P (467.33755700000006)
(2-Hexanoyloxy-3-octoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] nonanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-nonoxypropan-2-yl] octanoate
(3-Nonoxy-2-pentanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] pentanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-undecoxypropan-2-yl] hexanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-tridecoxypropan-2-yl] butanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-decoxypropan-2-yl] heptanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-pentadecoxypropan-2-yl] acetate
(2-Propanoyloxy-3-undecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
(2-Butanoyloxy-3-decoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-tetradecoxypropan-2-yl] propanoate
(1alpha,5xi,6beta,9xi,10xi,14alpha)-20-Ethyl-4-(hydroxymethyl)-1,6,14,16-tetramethoxyaconitane-7,8-diol
C25H41NO7 (467.28828760000005)
(1S,2R,3R,4S,5R,6S,8R,9S,10R,13S,16S,17R,18S)-11-ethyl-4,6,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecane-8,9,16-triol
C25H41NO7 (467.28828760000005)
(1S,4S,5R,6R,8R,9S,10S,13S,16S,17R,18R)-11-ethyl-13-(hydroxymethyl)-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecane-8,9-diol
C25H41NO7 (467.28828760000005)
2-[Hydroxy-[3-hydroxy-2-(propanoylamino)tetradecoxy]phosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(octanoylamino)nonoxy]phosphoryl]oxyethyl-trimethylazanium
2-[(2-Acetamido-3-hydroxypentadecoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-(Butanoylamino)-3-hydroxytridecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-(Heptanoylamino)-3-hydroxydecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(nonanoylamino)octoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[2-(Hexanoylamino)-3-hydroxyundecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[Hydroxy-[3-hydroxy-2-(pentanoylamino)dodecoxy]phosphoryl]oxyethyl-trimethylazanium
Aconitane-7,8,14-triol, 20-ethyl-4-(methoxymethyl)-1,6,16-trimethoxy-, (1-alpha,6-beta,14-alpha,16-beta)-
C25H41NO7 (467.28828760000005)
1-[(4As,5R,7S,8aR)-5-[[(1S,5S,9S,11R,13S,17R)-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.02,7.013,17]heptadec-6-en-5-yl]methyl]-7-methyl-3,4,4a,5,6,7,8,8a-octahydro-2H-quinolin-1-yl]ethanone
C30H49N3O (467.38754240000003)
Oxetacaine
C28H41N3O3 (467.3147756000001)
C - Cardiovascular system > C05 - Vasoprotectives > C05A - Agents for treatment of hemorrhoids and anal fissures for topical use > C05AD - Local anesthetics D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent Same as: D01152
LysoPC(14:0/0:0)
A lysophosphatidylcholine 14:0 in which the acyl group specified is myristoyl. The major species at pH 7.3. LysoPC(14:0/0:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. LysoPC(14:0/0:0) has potent antispasmodic effect[1].
2-tetradecanoyl-sn-glycero-3-phosphocholine
A 2-acyl-sn-glycero-3-phosphocholine in which the acyl group is specified as tertadecanoyl (myristoyl).
1-dodecyl-2-acetyl-sn-glycero-3-phosphocholine
A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine in which the alkyl group is specified as dodecyl.
1-octadecyl-sn-glycero-3-phosphoethanolamine
C23H50NO6P (467.33755700000006)
1-pentadecyl-sn-glycero-3-phosphocholine
C23H50NO6P (467.33755700000006)
1-(2-methoxy-5Z-hexadecenyl)-sn-glycero-3-phosphoethanolamine
1-(2-methoxy-6Z-hexadecenyl)-sn-glycero-3-phosphoethanolamine
lysophosphatidylcholine 14:0
A lysophosphatidylcholine in which the remaining acyl group is specified as tetradecanoyl (myristoyl). If R1 is the acyl group and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is the acyl group then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.
1-Heptadecanoyl-sn-glycero-3-phosphoethanolamine
A 1-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as heptadecanoyl.
1-heptadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion
A 1-acyl-sn-glycero-3-phosphoethanolamine zwitterion obtained by transfer of a proton from the amino to the phosphate group of 1-heptadecanoyl-sn-glycero-3-phosphoethanolamine; major species at pH 7.3.
PE(17:0)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
LdMePE(16:0)
C23H50NO6P (467.33755700000006)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
LdMePE(15:0)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Glycodeoxycholic acid (monohydrate)
Glycodeoxycholic acid monohydrate is a nuclear receptor ligand. Glycodeoxycholic acid monohydrate is a nuclear receptor ligand.
(3s,6s,9r)-5,8,11-trihydroxy-3-isopropyl-6,9-bis(2-methylpropyl)-13-pentyl-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18r)-11-ethyl-13-(hydroxymethyl)-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9-diol
C25H41NO7 (467.28828760000005)
(1s,2r,3r,4r,5s,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9-triol
C25H41NO7 (467.28828760000005)
(1r,2s,3s,4s,5r,6r,8s,9r,10r,13r,16s,17s,18s)-11-ethyl-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9-triol
C25H41NO7 (467.28828760000005)
(1s,2r,3r,4s,5s,6s,8r,10s,13s,16s,17r,18s)-11-ethyl-6,8,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,9,16-triol
C25H41NO7 (467.28828760000005)
(10s)-10-{2-[(1s,2r,4as,8ar)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]ethyl}-9-methoxy-3,10-dimethyl-1,3,5,7,9-pentaazatricyclo[6.4.1.0⁴,¹³]trideca-4,6,8(13)-trien-2-one
(1s,2s,3s,4s,5s,6r,8s,9s,10s,13s,16r,17r,18r)-11-ethyl-4,6,8-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-9,16,18-triol
C25H41NO7 (467.28828760000005)
(1r,3as,3bs,5as,7s,9ar,9bs,11as)-1-[(1r)-1-(3-hydroxy-5-methylpyridin-2-yl)ethyl]-9a,11a-dimethyl-5-oxo-tetradecahydrocyclopenta[a]phenanthren-7-yl acetate
C29H41NO4 (467.30354260000007)
(2e,4e,10s)-10-[(2s,4s,5s,6s,8r,9s,10r)-4,10-dihydroxy-5,8,9-trimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-4-ethyl-6-hydroxy-8-methylundeca-2,4-dienimidic acid
5,8,11-trihydroxy-9-isopropyl-6-methyl-13-(octan-2-yl)-3-(sec-butyl)-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
1-[5-({11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadec-6-en-5-yl}methyl)-7-methyl-octahydro-2h-quinolin-1-yl]ethanone
C30H49N3O (467.38754240000003)
(1s,2s,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-13-(hydroxymethyl)-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9-diol
C25H41NO7 (467.28828760000005)
(9s,10s,12s,14r,15z,26s)-9,19,21,26-tetramethyl-1-azacyclohexacosa-1,3,5,7,15,17,19,21,23-nonaene-2,10,12,14-tetrol
C29H41NO4 (467.30354260000007)
(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-4,6,16-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9,18-triol
C25H41NO7 (467.28828760000005)
(1r,2s,3s,4s,5r,6r,8s,9s,10s,13s,14r,16r,17r,18r)-11-ethyl-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,14-triol
C25H41NO7 (467.28828760000005)
(1s,2r,3r,4s,5s,6s,8r,9r,10r,13r,14r,16s,17s,18s)-11-ethyl-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,14-triol
C25H41NO7 (467.28828760000005)
(3s,3'r,3'as,6's,6as,6br,7'ar,9r,11as,11br)-3',6',10,11b-tetramethyl-11-oxo-1,2,3,3'a,4,4',5',6,6',6a,6b,7,7',7'a,8,11a-hexadecahydro-3'h-spiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridin]-3-yl acetate
C29H41NO4 (467.30354260000007)
1-{4-[(1r,3as,7r,9ar,9br,11as)-7-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-1h-pyrrol-2-yl}-2-hydroxy-2-methylpropan-1-one
11-ethyl-4,6,16,18-tetramethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-2,8,9-triol
C25H41NO7 (467.28828760000005)
(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-13-(hydroxymethyl)-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9-diol
C25H41NO7 (467.28828760000005)
11-ethyl-4,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-6,8,9-triol
C25H41NO7 (467.28828760000005)
(1s,2r,3r,4s,5s,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9-triol
C25H41NO7 (467.28828760000005)
(10s)-10-{2-[(1s,2r,4ar,8ar)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]ethyl}-9-methoxy-3,10-dimethyl-1,3,5,7,9-pentaazatricyclo[6.4.1.0⁴,¹³]trideca-4,6,8(13)-trien-2-one
11-ethyl-4,6,16-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9,18-triol
C25H41NO7 (467.28828760000005)
(6s,18s)-11-ethyl-4,6,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9,16-triol
C25H41NO7 (467.28828760000005)
11-ethyl-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9-triol
C25H41NO7 (467.28828760000005)
(1s,2r,3s,4r,5r,6r,8r,9s,13s,16r,17r,18r)-11-ethyl-4,6,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9,16-triol
C25H41NO7 (467.28828760000005)
3-[(2r,6s)-6-[(3s,5r)-3,5-dimethylheptyl]oxan-2-yl]-4-hydroxy-1-methyl-5-[(2r,3r,4s,5s)-2,3,4,5-tetrahydroxycyclopentyl]pyridin-2-one
C25H41NO7 (467.28828760000005)
11-ethyl-18,20-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.2⁴,⁸.0¹,¹⁰.0²,⁶.0¹³,¹⁷]icosane-5,8,9,16-tetrol
C25H41NO7 (467.28828760000005)
(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-4,6,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9,16-triol
C25H41NO7 (467.28828760000005)
(1s,2s,3s,4s,5r,6r,8s,9s,10s,13s,16s,17r,18r)-11-ethyl-6,8,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,9,16-triol
C25H41NO7 (467.28828760000005)
(1r,2r,3r,4s,5r,6s,8r,9s,10s,13r,14r,17s,18s)-11-ethyl-4,6,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9,14-triol
C25H41NO7 (467.28828760000005)
11-ethyl-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,14-triol
C25H41NO7 (467.28828760000005)
11-ethyl-4,6,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9,14-triol
C25H41NO7 (467.28828760000005)
11-ethyl-4,6,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9,16-triol
C25H41NO7 (467.28828760000005)
(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18r)-11-ethyl-4,6,8-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-9,16,18-triol
C25H41NO7 (467.28828760000005)
2-(2-{12,14,14,19-tetramethyl-8,19-diazapentacyclo[7.7.3.0¹,⁹.0²,⁷.0¹⁰,¹⁵]nonadeca-2,4,6,11-tetraen-16-yl}-1h-indol-3-yl)ethanol
(1s,2r,3r,4s,5r,6s,8r,9r,10s,13s,16s,17r,18s)-11-ethyl-4,6,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9,16-triol
C25H41NO7 (467.28828760000005)
(1s,2r,3r,4s,5r,6s,8r,9r,10s,13r,16s,17r,18s)-11-ethyl-13-(hydroxymethyl)-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9-diol
C25H41NO7 (467.28828760000005)
(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18r)-11-ethyl-4,6,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9,16-triol
C25H41NO7 (467.28828760000005)
11-ethyl-13-(hydroxymethyl)-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9-diol
C25H41NO7 (467.28828760000005)
6,18-dimethoxy-13-(methoxymethyl)-11-propyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9,16-tetrol
C25H41NO7 (467.28828760000005)
11-ethyl-6,8,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,9,16-triol
C25H41NO7 (467.28828760000005)
(2e,4e)-10-[(2r,4s,5s,6s,8r,9s,10r)-4,10-dihydroxy-5,8,9-trimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-4-ethyl-8-(hydroxymethyl)undeca-2,4-dienimidic acid
(1r,2s,3s,4s,5r,6s,8r,9r,10s,13r,16s,17r,18s)-11-ethyl-4,6,16,18-tetramethoxy-13-methyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-2,8,9-triol
C25H41NO7 (467.28828760000005)
1-[(4as,5r,7s,8ar)-5-{[(1s,2s,5r,9s,11r,13s,17r)-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadec-6-en-5-yl]methyl}-7-methyl-octahydro-2h-quinolin-1-yl]ethanone
C30H49N3O (467.38754240000003)
2-{2-[(1s,9r,10s,15r,16r)-12,14,14,19-tetramethyl-8,19-diazapentacyclo[7.7.3.0¹,⁹.0²,⁷.0¹⁰,¹⁵]nonadeca-2,4,6,11-tetraen-16-yl]-1h-indol-3-yl}ethanol
(1s,2r,4s,5r,6r,8r,9s,10s,13s,16s,17r,18s,20s)-11-ethyl-18,20-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.2⁴,⁸.0¹,¹⁰.0²,⁶.0¹³,¹⁷]icosane-5,8,9,16-tetrol
C25H41NO7 (467.28828760000005)
(2e,4e,10s)-10-[(2s,4s,5s,6s,8r,9s,10r)-4,10-dihydroxy-5,8,9-trimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-4-ethyl-8-hydroxy-8-methylundeca-2,4-dienimidic acid
(6s,9s)-3-[(2s)-butan-2-yl]-5,8,11-trihydroxy-9-isopropyl-6-methyl-13-(octan-2-yl)-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
(1r,3as,3br,5ar,7s,9ar,9br,11ar)-1-[(1r)-1-(3-hydroxy-5-methylpyridin-2-yl)ethyl]-9a,11a-dimethyl-5-oxo-tetradecahydrocyclopenta[a]phenanthren-7-yl acetate
C29H41NO4 (467.30354260000007)
3',6',10,11b-tetramethyl-11-oxo-1,2,3,3'a,4,4',5',6,6',6a,6b,7,7',7'a,8,11a-hexadecahydro-3'h-spiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridin]-3-yl acetate
C29H41NO4 (467.30354260000007)
1-[(4ar,5r,7s,8as)-5-{[(1s,2r,5r,9s,11r,13s,17r)-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadec-6-en-5-yl]methyl}-7-methyl-octahydro-2h-quinolin-1-yl]ethanone
C30H49N3O (467.38754240000003)
(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16r,17r,18s)-11-ethyl-13-(hydroxymethyl)-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9-diol
C25H41NO7 (467.28828760000005)
(2e,4e)-10-[(2s,4s,5s,6s,8r,9s,10r)-4,10-dihydroxy-5,8,9-trimethyl-1,7-dioxaspiro[5.5]undecan-2-yl]-4-ethyl-8-(hydroxymethyl)undeca-2,4-dienimidic acid
(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16r,17r,18s)-11-ethyl-4,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-6,8,9-triol
C25H41NO7 (467.28828760000005)
(1s,2r,3r,4s,5s,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-6,8,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,9,16-triol
C25H41NO7 (467.28828760000005)
n-(2-{[(2s)-1-[(2s,3s)-3-dodecyl-4-oxooxetan-2-yl]nonan-2-yl]oxy}-2-oxoethyl)carboximidic acid
C27H49NO5 (467.36105440000006)
1-[1-(3-hydroxy-5-methylpyridin-2-yl)ethyl]-9a,11a-dimethyl-5-oxo-tetradecahydrocyclopenta[a]phenanthren-7-yl acetate
C29H41NO4 (467.30354260000007)
(1s,2r,3r,4s,5s,6s,8r,9s,10s,13s,16r,17r,18s)-11-ethyl-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9-triol
C25H41NO7 (467.28828760000005)
1-[(4ar,5r,7s,8as)-5-{[(1r,2r,5r,9s,11r,13s,17r)-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadec-6-en-5-yl]methyl}-7-methyl-octahydro-2h-quinolin-1-yl]ethanone
C30H49N3O (467.38754240000003)
(5s)-5-(6-aminopurin-9-yl)-1-(4-hydroxy-3-methoxyphenyl)tetradecan-3-one
C26H37N5O3 (467.28962520000005)
3-[6-(3,5-dimethylheptyl)oxan-2-yl]-4-hydroxy-1-methyl-5-(2,3,4,5-tetrahydroxycyclopentyl)pyridin-2-one
C25H41NO7 (467.28828760000005)
(1r,2r,3r,4s,5s,6s,8r,9r,10r,13s,16r,17s,18s)-11-ethyl-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9-triol
C25H41NO7 (467.28828760000005)
1-[(4ar,5r,7s,8as)-5-{[(1s,5r,9s,11r,13s,17r)-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadec-6-en-5-yl]methyl}-7-methyl-octahydro-2h-quinolin-1-yl]ethanone
C30H49N3O (467.38754240000003)
(1s,5r,6s,8r,9s,13s,16s)-11-ethyl-13-(hydroxymethyl)-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-8,9-diol
C25H41NO7 (467.28828760000005)
13-(hydroxymethyl)-6,16,18-trimethoxy-11-propyl-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,8,9-triol
C25H41NO7 (467.28828760000005)
